205 related articles for article (PubMed ID: 35973998)
1. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.
Yedier-Bayram O; Gokbayrak B; Kayabolen A; Aksu AC; Cavga AD; Cingöz A; Kala EY; Karabiyik G; Günsay R; Esin B; Morova T; Uyulur F; Syed H; Philpott M; Cribbs AP; Kung SHY; Lack NA; Onder TT; Bagci-Onder T
Cell Death Dis; 2022 Aug; 13(8):710. PubMed ID: 35973998
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs.
Kurata JS; Lin RJ
RNA; 2018 Jul; 24(7):966-981. PubMed ID: 29720387
[TBL] [Abstract][Full Text] [Related]
4. Generation of an arrayed CRISPR-Cas9 library targeting epigenetic regulators: from high-content screens to in vivo assays.
Henser-Brownhill T; Monserrat J; Scaffidi P
Epigenetics; 2017; 12(12):1065-1075. PubMed ID: 29327641
[TBL] [Abstract][Full Text] [Related]
5. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
Graf R; Li X; Chu VT; Rajewsky K
Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
[TBL] [Abstract][Full Text] [Related]
6. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
Kiessling MK; Schuierer S; Stertz S; Beibel M; Bergling S; Knehr J; Carbone W; de Vallière C; Tchinda J; Bouwmeester T; Seuwen K; Rogler G; Roma G
BMC Genomics; 2016 Sep; 17(1):723. PubMed ID: 27613601
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 as a tool to dissect cancer mutations.
Sayed S; Paszkowski-Rogacz M; Schmitt LT; Buchholz F
Methods; 2019 Jul; 164-165():36-48. PubMed ID: 31078796
[TBL] [Abstract][Full Text] [Related]
8. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.
Vemuri S; Srivastava R; Mir Q; Hashemikhabir S; Dong XC; Janga SC
Methods; 2020 Jun; 178():104-113. PubMed ID: 31494246
[TBL] [Abstract][Full Text] [Related]
9. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
Yim S; Hwang W; Han N; Lee D
Front Immunol; 2022; 13():884561. PubMed ID: 35651625
[TBL] [Abstract][Full Text] [Related]
10. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.
Dai M; Yan G; Wang N; Daliah G; Edick AM; Poulet S; Boudreault J; Ali S; Burgos SA; Lebrun JJ
Nat Commun; 2021 May; 12(1):3055. PubMed ID: 34031411
[TBL] [Abstract][Full Text] [Related]
11. Applications of CRISPR Epigenome Editors in Tumor Immunology and Autoimmunity.
Yahsi B; Palaz F; Dincer P
ACS Synth Biol; 2024 Feb; 13(2):413-427. PubMed ID: 38298016
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level.
Yuen G; Khan FJ; Gao S; Stommel JM; Batchelor E; Wu X; Luo J
Nucleic Acids Res; 2017 Nov; 45(20):12039-12053. PubMed ID: 29036671
[TBL] [Abstract][Full Text] [Related]
13. Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen.
Barkovskaya A; Goodwin CM; Seip K; Hilmarsdottir B; Pettersen S; Stalnecker C; Engebraaten O; Briem E; Der CJ; Moestue SA; Gudjonsson T; Maelandsmo GM; Prasmickaite L
Mol Oncol; 2021 Aug; 15(8):2026-2045. PubMed ID: 33759347
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a pig CRISPR/Cas9 knockout library for functional gene screening in pig cells.
Yu C; Zhong H; Yang X; Li G; Wu Z; Yang H
Biotechnol J; 2022 Jul; 17(7):e2100408. PubMed ID: 34705337
[TBL] [Abstract][Full Text] [Related]
15. Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens.
Fortin JP; Tan J; Gascoigne KE; Haverty PM; Forrest WF; Costa MR; Martin SE
Genome Biol; 2019 Jan; 20(1):21. PubMed ID: 30683138
[TBL] [Abstract][Full Text] [Related]
16. 3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer.
Llinàs-Arias P; Ensenyat-Méndez M; Orozco JIJ; Íñiguez-Muñoz S; Valdez B; Wang C; Mezger A; Choi E; Tran YZ; Yao L; Bonath F; Olsen RA; Ormestad M; Esteller M; Lupien M; Marzese DM
BMC Genom Data; 2023 Nov; 24(1):61. PubMed ID: 37919672
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
[TBL] [Abstract][Full Text] [Related]
18. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
[No Abstract] [Full Text] [Related]
19. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens.
Hart T; Tong AHY; Chan K; Van Leeuwen J; Seetharaman A; Aregger M; Chandrashekhar M; Hustedt N; Seth S; Noonan A; Habsid A; Sizova O; Nedyalkova L; Climie R; Tworzyanski L; Lawson K; Sartori MA; Alibeh S; Tieu D; Masud S; Mero P; Weiss A; Brown KR; Usaj M; Billmann M; Rahman M; Constanzo M; Myers CL; Andrews BJ; Boone C; Durocher D; Moffat J
G3 (Bethesda); 2017 Aug; 7(8):2719-2727. PubMed ID: 28655737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
